Engineering and expression of a human rotavirus candidate vaccine in Nicotiana benthamiana Other viruses (e.g. pox, papilloma, parvo, reoviridae)

Virology Journal

Volumn 12, Issue 1, 2015, Pages

  Pêra, Francisco F P G ^a   Mutepfa, David L R ^a   Khan, Ayesha M ^a   Els, Johann H ^a   Mbewana, Sandiswa ^a   Van Dijk, Alberdina A A ^b   Rybicki, Edward P ^a,c   Hitzeroth, Inga I ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b NORTH WEST UNIVERSITY   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

PLANT EXTRACT; PROTEIN VP2; PROTEIN VP4; PROTEIN VP6; PROTEIN VP7; ROTAVIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS PROTEIN VP2 VIRUS PROTEIN VP8 AMINO TERMINAL FUSION PROTEIN; VIRUS PROTEIN VP2 VIRUS PROTEIN VP8 CARBOXY TERMINAL FUSION PROTEIN; VIRUS PROTEIN VP6 VIRUS PROTEIN VP8 FUSION PROTEIN; CAPSID PROTEIN; HYBRID PROTEIN; RECOMBINANT VACCINE; VIRUS ANTIGEN; VIRUS LIKE PARTICLE VACCINE; VP2 PROTEIN, ROTAVIRUS; VP6 PROTEIN, ROTAVIRUS;

ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DRUG DETERMINATION; EXPRESSION VECTOR; HUMAN ROTAVIRUS; IMMUNOGENICITY; NICOTIANA BENTHAMIANA; NONHUMAN; PLANT EXPRESSION SYSTEM; PLANT LEAF; PROTEIN AGGREGATION; PROTEIN ASSEMBLY; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TRANSMISSION ELECTRON MICROSCOPY; VACCINE PRODUCTION; VIRION; VIRUS EXPRESSION; VIRUS PARTICLE; VIRUS STRAIN; WESTERN BLOTTING; WILTING; CLASSIFICATION; DNA SEQUENCE; GASTROENTERITIS; GENETICS; GENOTYPE; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; MOLECULAR GENETICS; ROTAVIRUS; ROTAVIRUS INFECTIONS; TOBACCO; VIROLOGY;

ANTIGENS, VIRAL; CAPSID PROTEINS; GASTROENTERITIS; GENOTYPE; HUMANS; MICROSCOPY, ELECTRON, TRANSMISSION; MOLECULAR SEQUENCE DATA; RECOMBINANT FUSION PROTEINS; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; SEQUENCE ANALYSIS, DNA; TOBACCO; VACCINES, SYNTHETIC; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84949238278     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/s12985-015-0436-8     Document Type: Article

References (63)

1. Bishop RF, Davidson GP. Virus-particles in epithelial-cells of duodenal mucosa from children with acute non-bacterial gastroenteritis. Lancet. 1973;2(7841):1281-3.
2. Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis. 2003;9(5):565-72.
3. Tate JE, Burton AH, Boschi-Pinto C, Steele AD, Duque J, Parashar UD, et al. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(2):136-41. doi: 10.1016/S1473-3099.
4. Waggie Z, Hawkridge A, Hussey GD. Review of rotavirus studies in Africa: 1976-2006. J Infect Dis. 2010;202(Supplement 1):S23-33.
5. Kosek M, Bern C, Guerrant RL. The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000. Bull World Health Organ. 2003;81(3):197-204.
6. Walker CLF, Rudan I, Liu L, Nair H, Theodoratou E, Bhutta ZA, et al. Childhood pneumonia and diarrhoea 1 global burden of childhood pneumonia and diarrhoea. Lancet. 2013;381(9875):1405-16. doi: 10.1016/S0140-6736.
7. Ruiz MC, Leon T, Diaz Y, Michelangeli F. Molecular biology of rotavirus entry and replication. Sci World J. 2009;9:1476-97. doi: 10.1100/tsw.2009.158.
8. Wen X, Cao D, Jones RW, Li J, Szu S, Hoshino Y. Construction and characterization of human rotavirus recombinant VP8∗subunit parenteral vaccine candidates. Vaccine. 2012;30(43):6121-6. doi: 10.1016/j.vaccine.2012.07.078.
9. Lentz EM, Mozgovoj MV, Bellido D, Dus Santos MJ, Wigdorovitz A, Bravo-Almonacid FF. VP8∗antigen produced in tobacco transplastomic plants confers protection against bovine rotavirus infection in a suckling mouse model. J Biotechnol. 2011;156(2):100-7.
10. Matthijnssens J, Otto P, Ciarlet M, Desselberger U, Van Ranst M, Johne R. VP6-sequence-based cutoff values as a criterion for rotavirus species demarcation. Arch Virol. 2012;157(6):1177-82. doi: 10.1007/s00705-012-1273-3.
11. Jere KC, Mlera L, O'Neill HG, Potgieter AC, Page NA, Seheri ML, et al. Whole genome analyses of African G2, G8, G9, and G12 rotavirus strains using sequence-independent amplification and 454 (R) pyrosequencing. J Med Virol. 2011;83(11):2018-42. doi: 10.1002/Jmv.22207.
12. Hoshino Y, Kapikian AZ. Rotavirus serotypes: classification and importance in epidemiology, immunity, and vaccine development. J Health Popul Nutr. 2000;18(1):5-14.
13. Matthijnssens J, Ciarlet M, McDonald SM, Attoui H, Banyai K, Brister JR, et al. Uniformity of rotavirus strain nomenclature proposed by the Rotavirus Classification Working Group (RCWG). Arch Virol. 2011;156(8):1397-413.
14. Matthijnssens J, Mino S, Papp H, Potgieter C, Novo L, Heylen E, et al. Complete molecular genome analyses of equine rotavirus A strains from different continents reveal several novel genotypes and a largely conserved genotype constellation. J Gen Virol. 2012;93(Pt 4):866-75.
15. Glass RI, Parashar UD, Bresee JS, Turcios R, Fischer TK, Widdowson MA, et al. Rotavirus vaccines: current prospects and future challenges. Lancet. 2006;368(9532):323-32.
16. Page N, Esona M, Armah G, Nyangao J, Mwenda J, Sebunya T, et al. Emergence and characterization of serotype G9 rotavirus strains from Africa. J Infect Dis. 2010;202(Suppl):S55-63.
17. Todd S, Page NA, Duncan SA, Peenze I, Cunliffe NA. Rotavirus strain types circulating in Africa: Review of studies published during 1997-2006. J Infect Dis. 2010;202(Suppl):S34-42.
18. Seheri LM, Page N, Dewar JB, Geyer A, Nemarude AL, Bos P, et al. Characterization and molecular epidemiology of rotavirus strains recovered in Northern Pretoria, South Africa during 2003-2006. J Infect Dis. 2010;202(Supplement 1):S139-47.
19. Steele AD, Ivanoff B. Rotavirus strains circulating in Africa during 1996-1999: emergence of G9 strains and P[6] strains. Vaccine. 2003;21:361-7. doi: 10.1016/s0264.
20. Madhi SA, Cunliffe NA, Steele D, Witte D, Kirsten M, Louw C, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. New Engl J Med. 2010;362(4):289-98. doi: 10.1056/Nejmoa0904797.
21. Armah GE, Sow SO, Breiman RF, Dallas MJ, Tapia MD, Feikin DR, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;376(9741):606-14. doi: 10.1016/s0140-6736(10)60889-6.
22. Vesikari T, Clark HF, Offit PA, Dallas MJ, DiStefano DJ, Goveia MG, et al. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants. Vaccine. 2006;24(22):4821-9.
23. Steele AD, Neuzil KM, Cunliffe NA, Madhi SA, Bos P, Ngwira B et al. Human rotavirus vaccine Rotarix (TM) provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial. BMC Infect Dis. 2012;12. Doi 10.1186/1471-2334-12-213
24. Babji S, Kang G. Rotavirus vaccination in developing countries. Curr Opin Virol. 2012;2(4):443-8. doi: 10.1016/j.coviro.2012.05.005.
25. Potgieter AC, Page NA, Liebenberg J, Wright IM, Landt O, van Dijk AA. Improved strategies for sequence-independent amplification and sequencing of viral double-stranded RNA genomes. J Gen Virol. 2009;90(Pt 6):1423-32.
26. Hemming M, Vesikari T. Vaccine derived human-bovine double reassortant rotavirus in infants with acute gastroenteritis. Pediatr Infect Dis J. 2012;31:992.
27. El-Attar L, Oliver SL, Mackie A, Charpilienne A, Poncet D, Cohen J, et al. Comparison of the efficacy of rotavirus VLP vaccines to a live homologous rotavirus vaccine in a pig model of rotavirus disease. Vaccine. 2009;27(24):3201-8.
28. Crawford SE, Labbe M, Cohen J, Burroughs MH, Zhou YJ, Estes MK. Characterization of virus-like particles produced by the expression of rotavirus capsid proteins in insect cells. J Virol. 1994;68(9):5945-52.
29. Bertolotti-Ciarlet A, Ciarlet M, Crawford SE, Conner ME, Estes MK. Immunogenicity and protective efficacy of rotavirus 2/6-virus-like particles produced by a dual baculovirus expression vector and administered intramuscularly, intranasally, or orally to mice. Vaccine. 2003;21(25-26):3885-900.
30. Rodriguez-Limas WA, Tyo KE, Nielsen J, Ramirez OT, Palomares LA. Molecular and process design for rotavirus-like particle production in Saccharomyces cerevisiae. Microb Cell Fact. 2011;10:33.
31. Rybicki EP. Plant-made vaccines for humans and animals. Plant Biotechnol J. 2010;8(5):620-37.
32. Matsumura T, Itchoda N, Tsunemitsu H. Production of immunogenic VP6 protein of bovine group A rotavirus in transgenic potato plants. Arch Virol. 2002;147(6):1263-70.
33. O'Brien GJ, Bryant CJ, Voogd C, Greenberg HB, Gardner RC, Bellamy AR. Rotavirus VP6 expressed by PVX vectors in Nicotiana benthamiana coats PVX rods and also assembles into viruslike particles. Virology. 2000;270(2):444-53.
34. Zhou B, Zhang Y, Wang X, Dong J, Wang B, Han C, et al. Oral administration of plant-based rotavirus VP6 induces antigen-specific IgAs, IgGs and passive protection in mice. Vaccine. 2010;28(37):6021-7.
35. Saldana S, Esquivel GF, Olivera Flores TJ, Arias N, Lopez S, Arias C, et al. Production of rotavirus-like particles in tomato (Lycopersicon esculentum L.) fruit by expression of capsid proteins VP2 and VP6 and immunological studies. Viral Immunol. 2006;19(1):42-53.
36. Takeda A, Sugiyama K, Nagano H, Mori M, Kaido M, Mise K, et al. Identification of a novel RNA silencing suppressor, NSs protein of Tomato spotted wilt virus. FEBS Lett. 2002;532(1-2):75-9.
37. Emslie KR, Miller JM, Slade MB, Dormitzer PR, Greenberg HB, Williams KL. Expression of the rotavirus SA11 protein VP7 in the simple eukaryote Dictyostelium discoideum. J Virol. 1995;69(3):1747-54.
38. McCrae MA, McCorquodale JG. Expression of a major bovine rotavirus neutralisation antigen (VP7c) in Escherichia coli. Gene. 1987;55(1):9-18.
39. Maass DR, Atkinson PH. Retention by the endoplasmic reticulum of rotavirus VP7 is controlled by three adjacent amino-terminal residues. J Virol. 1994;68(1):366-78.
40. Zambrano JL, Diaz Y, Pena F, Vizzi E, Ruiz MC, Michelangeli F, et al. Silencing of rotavirus NSP4 or VP7 expression reduces alterations in Ca2+ homeostasis induced by infection of cultured cells. J Virol. 2008;82(12):5815-24. doi: 10.1128/JVI.02719-07.
41. Perez JF, Chemello ME, Liprandi F, Ruiz MC, Michelangeli F. Oncosis in MA104 cells is induced by rotavirus infection through an increase in intracellular Ca2+ concentration. Virology. 1998;252(1):17-27.
42. Choi NW, Estes MK, Langridge WH. Synthesis and assembly of a cholera toxin B subunit-rotavirus VP7 fusion protein in transgenic potato. Mol Biotechnol. 2005;31(3):193-202.
43. Li JT, Fei L, Mou ZR, Wei J, Tang Y, He HY, et al. Immunogenicity of a plant-derived edible rotavirus subunit vaccine transformed over fifty generations. Virology. 2006;356(1-2):171-8.
44. Wu YZ, Li JT, Mou ZR, Fei L, Ni B, Geng M, et al. Oral immunization with rotavirus VP7 expressed in transgenic potatoes induced high titers of mucosal neutralizing IgA. Virology. 2003;313(2):337-42.
45. Shoja Z, Tagliamonte M, Jalilvand S, Mollaei-Kandelous Y, De Stradis A, Tornesello ML, et al. Formation of self-assembled triple-layered rotavirus-like particles (tlRLPs) by constitutive co-expression of VP2, VP6, and VP7 in stably transfected high-five insect cell lines. J Med Virol. 2015;87(1):102-11. doi: 10.1002/jmv.23973.
46. Istrate C, Hinkula J, Charpilienne A, Poncet D, Cohen J, Svensson L, et al. Parenteral administration of RF 8-2/6/7 rotavirus-like particles in a one-dose regimen induce protective immunity in mice. Vaccine. 2008;26(35):4594-601. doi: 10.1016/j.vaccine.2008.05.089.
47. Parez N, Fourgeux C, Mohamed A, Dubuquoy C, Pillot M, Dehee A, et al. Rectal immunization with rotavirus virus-like particles induces systemic and mucosal humoral immune responses and protects mice against rotavirus infection. J Virol. 2006;80(4):1752-61. doi: 10.1128/jvi.80.4.1752-1761.2006.
48. Kovacs-Nolan J, Mine Y. Tandem copies of a human rotavirus VP8 epitope can induce specific neutralizing antibodies in BALB/c mice. Biochim Biophys Acta Gen Subj. 2006;1760(12):1884-93. doi: 10.1016/j.bbagen.2006.07.015.
49. Lepault J. Structural polymorphism of the major capsid protein of rotavirus. EMBO J. 2001;20(7):1498-507. doi: 10.1093/emboj/20.7.1498.
50. Petitpas I, Lepault J, Vachette P, Charpilienne A, Mathieu M, Kohli E, et al. Crystallization and preliminary X-Ray analysis of rotavirus protein VP6. J Virol. 1998;72(9):7615-9.
51. Vieira HL, Estevao C, Roldao A, Peixoto CC, Sousa MF, Cruz PE, et al. Triple layered rotavirus VLP production: kinetics of vector replication, mRNA stability and recombinant protein production. J Biotechnol. 2005;120(1):72-82.
52. Saldaña S, Guadarrama FE, Flores TDJO, Arias N, López S, Arias C, et al. Production of rotavirus-like particles in tomato (Lycopersicon esculentum L.) fruit by expression of Capsid proteins VP2 and VP6 and immunological studies. Viral Immunol. 2006;19(1):42-53. doi: 10.1089/vim.2006.19.42.
53. Zhou H, Guo L, Wang M, Qu J, Zhao Z, Wang J, et al. Prime immunization with rotavirus VLP 2/6 followed by boosting with an adenovirus expressing VP6 induces protective immunization against rotavirus in mice. Virol J. 2011;8(1):3. doi: 10.1186/1743-422x-8-3.
54. Yuan L, Geyer A, Hodgins DC, Fan Z, Qian Y, Chang KO, et al. Intranasal administration of 2/6-rotavirus-like particles with mutant Escherichia coli heat-labile toxin (LT-R192G) induces antibody-secreting cell responses but not protective immunity in gnotobiotic pigs. J Virol. 2000;74(19):8843-53.
55. Conner ME, Zarley CD, Hu B, Parsons S, Drabinski D, Greiner S, et al. Virus-like particles as a rotavirus subunit vaccine. J Infect Dis. 1996;174(Supplement 1):S88-92. doi: 10.1093/infdis/174.supplement-1.s88.
56. Crawford SE, Estes MK, Ciarlet M, Barone C, O'Neal CM, Cohen J, et al. Heterotypic protection and induction of a broad heterotypic neutralization response by rotavirus-like particles. J Virol. 1999;73(6):4813-22.
57. Klose J, Wendt N, Kubald S, Krause E, Fechner K, Beyermann M, et al. Hexa-histidin tag position influences disulfide structure but not binding behavior of in vitro folded N-terminal domain of rat corticotropin-releasing factor receptor type 2a. Protein Sci. 2004;13(9):2470-5. doi: 10.1110/ps.04835904.
58. Chant A, Kraemer-Pecore CM, Watkin R, Kneale GG. Attachment of a histidine tag to the minimal zinc finger protein of the Aspergillus nidulans gene regulatory protein AreA causes a conformational change at the DNA-binding site. Protein Expr Purif. 2005;39(2):152-9. doi: 10.1016/j.pep.2004.10.017.
59. Wang J, Lin Y, Cai P, Wang H. Effects of vector fusion peptides on the conformation and immune reactivity of epitope-shuffled, recombinant multi-epitope antigens. Protein Pept Lett. 2011;18(1):73-83.
60. Maclean J, Koekemoer M, Olivier AJ, Stewart D, Hitzeroth II, Rademacher T, et al. Optimization of human papillomavirus type 16 (HPV-16) L1 expression in plants: comparison of the suitability of different HPV-16 L1 gene variants and different cell-compartment localization. J Gen Virol. 2007;88(Pt 5):1460-9.
61. Sainsbury F, Lomonossoff GP. Extremely high-level and rapid transient protein production in plants without the use of viral replication. Plant Physiol. 2008;148(3):1212-8. doi: 10.1104/pp.108.126284.
62. Regnard GL, Halley-Stott RP, Tanzer FL, Hitzeroth II, Rybicki EP. High level protein expression in plants through the use of a novel autonomously replicating geminivirus shuttle vector. Plant Biotechnol J. 2010;8(1):38-46. doi: 10.1111/j.1467-7652.2009.00462.x.
63. Prins M, Resende RD, Anker C, VanSchepen A, DeHaan P, Goldbach R. Engineered RNA-mediated resistance to tomato spotted wilt virus is sequence specific. Mol Plant Microbe. 1996;9(5):416-8. doi: 10.1094/Mpmi-9-0416.